Research programme: DNA interference therapies - Sierra Oncology

Drug Profile

Research programme: DNA interference therapies - Sierra Oncology

Alternative Names: PNT 100; PNT 200; PNT 300; PNT 400; PNT 500; PNT 600

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProNAi Therapeutics
  • Developer Sierra Oncology
  • Class Oligonucleotides
  • Mechanism of Action BIRC5 protein modulators; DNA modulators; KRAS protein modulators; Proto-oncogene protein c-bcl-2 modulators; STAT3 transcription factor modulators; Transforming growth factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 09 Jan 2017 ProNAi Therapeutics is now called Sierra Oncology
  • 03 Nov 2015 Marina Biotech has patent protection for SMARTICLES® delivery technology and for the composition of NOV 340 in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top